- First Patient dosed in Small Pharma’s Phase I study exploring intramuscular administration of SPL026
- The study will compare the profile of intramuscular versus intravenous SPL026 administration
- This study seeks to identify a target dose of SPL026 administered via IM injection
- The company’s current focus is exploring new therapeutic approaches for depression
- Small Pharma (DMT) is up over 5.50 per cent, trading at C$0.10 at 2:31 pm EST
Small Pharma (DMT) announced that the first patient has been dosed in its Phase I study exploring intermuscular administration of SPL026.
Small Pharma’s lead candidate, SPL026, is a proprietary synthetic formulation of DMT.
The goal of the study, being conducted in the United Kingdom, is to compare SPL026 delivered via IM versus IV administration in up to 14 healthy volunteers.
Dr. Carol Routledge, Chief Medical and Scientific Officer, commented on the study.
“IM injection of SPL026 may provide greater convenience for physicians, as well as potentially improve the treatment experience for some patients. This study seeks to identify a target dose of SPL026, administered via IM injection, that is well tolerated and delivers a consistent breakthrough psychedelic experience. By understanding parameters such as the duration and intensity of the psychedelic experience, we will be able to explore the potential application of IM SPL026 for treating mental health conditions.”
George Tziras, Chief Executive Officer, added,
“Patient access is core to our mission. It is reflected in our decision to focus on short-duration psychedelics delivered through different administration routes, with the goal of maximizing patient reach and convenience. With the Phase IIa study of IV SPL026 in Major Depressive Disorder now completed and results anticipated very soon, we are a step closer to understanding the potential efficacy of SPL026 as a depression treatment. These proof-of-concept results, combined with the results of our other SPL026 studies, will help guide our future clinical development and commercialization strategy.”
Small Pharma is a biotechnology company progressing a pipeline of short-acting psychedelic-assisted therapies for the treatment of mental health conditions. The company’s current focus is on exploring new therapeutic approaches for depression.
Small Pharma (DMT) is up over 5.50 per cent, trading at C$0.10 at 2:31 pm EST.
